TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TNDM is not a good buy right now for an impatient investor. The stock is sitting just above near-term support (~19.15) but remains technically weak (MACD below zero, RSI ~42, price below the pivot ~20.33), while the dominant near-term headline flow is negative (securities-fraud/class-action investigations tied to the prior device correction and governance/safety concerns). Options flow looks bullish (call-heavy volume; put/call OI < 1), but that reads more like speculative positioning than a confirmed trend reversal. With no Intellectia buy signals today and a probabilistic setup pointing to downside over the next month, the risk/reward is not favorable for buying immediately.
Intellectia Proprietary Trading Signals
Trend/structure: Momentum is weak-to-bearish but not in capitulation. MACD histogram is -0.21 (below 0), though it is negatively contracting (bearish momentum is easing, not reversing yet). RSI(6) at ~42 is neutral-to-weak, consistent with a fragile base rather than an uptrend. Key levels: Pivot 20.326 is the near-term line in the sand; current ~19.89 is below pivot, implying sellers still control the short-term tape. Immediate support is S1 19.15 (close by); if that breaks, S2 18.423 is the next downside magnet. Resistance sits at R1 21.503 then R2 22.23. MA/confirmation: Moving averages are converging, which often precedes a bigger move; however, without reclaiming the pivot/near resistance, the setup is not a clean long entry. Near-term pattern odds (provided): Similar-pattern projection shows ~-5.09% over the next month—another reason this is not an urgent buy at current levels.
Analyst tone/targets improving into 2026: multiple firms lifted price targets materially (many now around $21–$30+, with a high of $35), with several Buy/Outperform ratings citing product cycle/catalysts.
Institutional behavior: Hedge funds are reported as buying aggressively (buying amount up ~870.81% QoQ), which can provide support if fundamentals stabilize.
Business drivers cited by Street: Mobi adoption, algorithm strength in AID systems, potential pharmacy revenue/margin tailwinds, and an expected mid-year product launch (Mobi-T) referenced by analysts.
Upcoming event: QDEC 2025 earnings on 2026-02-19 (after hours) could reset expectations if guidance/traction improves.
keep sentiment pressured and can deter new buyers.
and close to support (19.15). A support break would likely accelerate downside toward ~18.
Short-horizon statistical outlook: Similar-candlestick analysis suggests a negative 1-month expectancy (~-5.09%).
Latest quarter: 2025/Q3. Growth: Revenue rose to $249.253M (+2.17% YoY), indicating modest top-line expansion rather than acceleration. Profitability: Net income fell to -$21.165M (down -8.97% YoY) and EPS declined to -0.31 (down -11.43% YoY), showing losses widened modestly. Margins: Gross margin improved to 53.88% (+5.46% YoY), a clear positive trend and a key area to watch for operating leverage. Bottom line: Margin improvement is encouraging, but the lack of meaningful revenue acceleration plus ongoing losses weakens the case for buying ahead of near-term uncertainty.
Recent trend: Wall Street has been raising price targets meaningfully since December 2025 into January 2026 (e.g., Goldman to $25 from $16; Bernstein to $25 from $18; Truist to $24 from $17; RBC to $30 from $25; Baird upgraded to Outperform with $30 from $18; Canaccord to $35 from $24; TD Cowen reiterated Buy and raised to $25). Ratings mix is improving but still split between Buy/Outperform and Neutral/Hold. Pros view: Product/cycle optimism (Mobi adoption, algorithm differentiation), potential margin tailwinds (pharmacy mix), and a 2026 catalyst slate underpin the higher targets. Cons view: Some firms remain Neutral/Hold and caution that expectations for 2026 may be too high (notably Citi’s caution), implying asymmetric risk if guidance doesn’t validate the new optimism. Influential trading check: No recent congress trading data available; insiders are reported as neutral (no significant recent trend).
